SUPPLEMENTARY FIGURE S1: Binding antibody responses to SARS-CoV-2 spike (Anti-S) following vaccination with ChAdOx1 (AZD1222).
SUPPLEMENTARY FIGURE S2: SAR-COV-2 variant Dynamics (Fig S2-A) and cumulative number of cases by COVID-19 zones (showing study sites 1 to 5).
SUPPLEMENTARY TABLE S1: Line listing of adverse events of special interest.
SUPPLEMENTARY TABLE S2: Line listing of serious adverse events.
SUPPLEMENTARY TABLE S3: Incidence (per 1,000 participant-years) of AE, localised and systemic adverse events by prior COVID infection status.
SUPPLEMENTARY TABLE S4: Sociodemographic characteristics of participants enrolled in the immunogenicity subcohort of the ChAdOx1(AZD1222) study.
SUPPLEMENTARY TABLE S5: geometric mean concentrations of Anti-Nucleocapsid antibody levels by dose and time (days) since first-dose.
SUPPLEMENTARY TABLE S6: geometric mean concentrations of Anti-Spike antibody levels by dose and time (days) since first-dose.